SCHEMBL6700560

SCHEMBL6700560

COc1ccccc1N1CCN(c2ccc(C(=O)N3CCNCC3)cc2NC(=O)Nc2ccccc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.60
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
POLB P06746 4/20 0.53
NAMPT P43490 1/20 0.53
MAPT P10636 6/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 1/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 3/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697460 0.85 TP53 (0.48) TP53KMT2AMEN1POLBNAMPT
SCHEMBL29968981 0.84 TP53 (0.66) TP53KMT2AMEN1POLBNAMPT
SCHEMBL6687418 0.84 TP53 (0.66) TP53KMT2AMEN1POLBNAMPT
SCHEMBL6701820 0.83 ALDH1A1 (0.50) TP53KMT2AMEN1POLBMAPT
SCHEMBL6703117 0.83 MAPT (0.47) TP53KMT2AMAPTKDM4EALDH1A1
SCHEMBL6694739 0.82 KMT2A (0.49) TP53KMT2AMEN1POLBMAPT
SCHEMBL6701730 0.82 KMT2A (0.48) TP53KMT2AMEN1MAPTKDM4E
SCHEMBL6701825 0.82 USP2 (0.50) TP53KMT2APOLBMAPTNPC1
SCHEMBL6805390 0.81 ALDH1A1 (0.49) TP53KMT2APOLBMAPTKDM4E
SCHEMBL6696478 0.81 ALDH1A1 (0.49) TP53KMT2APOLBNAMPTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235855-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 TP53 4604/4885KMT2A 4455/4885MEN1 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.